Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harriet Feilotter

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
The Journal of Molecular Diagnostics : JMD|December 24, 2022
A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing: Test Validation for the Clinical LaboratoryMashiat L Mimosa, Wafa Al-Ameri, Jared T Simpson, et al.
Current Pharmaceutical Design|June 12, 2012
The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response predictionSidney H Kennedy, Jonathan Downar, Kenneth R Evans, et al.
Journal of Psychiatric Research|December 24, 2018
Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatmentHelena Kyunghee Kim, Kathrin Tyryshkin, Nika Elmi, et al.
BMC Cancer|March 21, 2012
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerAlexandria M Haslehurst, Madhuri Koti, Moyez Dharsee, et al.
JCO Precision Oncology|August 23, 2024
Kinetic Profiling of <i>RAS</i> Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of <i>RAS</i> Mutations in Neo-<i>RAS</i>-Wildtype Metastatic Colorectal Cancer Is TransientFlorence T H Wu, James T Topham, Chris J O'Callaghan, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory PerspectiveDon Husereau, Yvonne Bombard, Tracy Stockley, et al.
Molecular Diagnosis & Therapy|October 4, 2022
Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer PatientsJoshua D Silvertown, Connie Lisle, Laura Semenuk, et al.
The Journal of Molecular Diagnostics : JMD|June 11, 2022
Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists: A Report of the Association for Molecular Pathology Training and Education CommitteePriya D Velu, Allison Cushman-Vokoun, Mark D Ewalt, et al.
Plos One|October 1, 2021
Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumoursJohn Bartlett, Yutaka Amemiya, Heleen Arts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2022
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal CancerJames T Topham, Chris J O'Callaghan, Harriet Feilotter, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
The Journal of Molecular Diagnostics : JMD|December 24, 2022
A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing: Test Validation for the Clinical LaboratoryMashiat L Mimosa, Wafa Al-Ameri, Jared T Simpson, et al.
Current Pharmaceutical Design|June 12, 2012
The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response predictionSidney H Kennedy, Jonathan Downar, Kenneth R Evans, et al.
Journal of Psychiatric Research|December 24, 2018
Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatmentHelena Kyunghee Kim, Kathrin Tyryshkin, Nika Elmi, et al.
BMC Cancer|March 21, 2012
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerAlexandria M Haslehurst, Madhuri Koti, Moyez Dharsee, et al.
JCO Precision Oncology|August 23, 2024
Kinetic Profiling of <i>RAS</i> Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of <i>RAS</i> Mutations in Neo-<i>RAS</i>-Wildtype Metastatic Colorectal Cancer Is TransientFlorence T H Wu, James T Topham, Chris J O'Callaghan, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory PerspectiveDon Husereau, Yvonne Bombard, Tracy Stockley, et al.
Molecular Diagnosis & Therapy|October 4, 2022
Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer PatientsJoshua D Silvertown, Connie Lisle, Laura Semenuk, et al.
The Journal of Molecular Diagnostics : JMD|June 11, 2022
Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists: A Report of the Association for Molecular Pathology Training and Education CommitteePriya D Velu, Allison Cushman-Vokoun, Mark D Ewalt, et al.
Plos One|October 1, 2021
Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumoursJohn Bartlett, Yutaka Amemiya, Heleen Arts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2022
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal CancerJames T Topham, Chris J O'Callaghan, Harriet Feilotter, et al.
Pageof 5